| 主权项 |
1. A method of treating a host infected with a host infected with HCV, comprising administering an effective amount of a ribofuranonucleoside of Formula (I):a pharmacologically acceptable salt thereof,wherein:
R is H, mono-, di-, or triphosphate; a stabilized phosphate; or phosphonate; X is O, S(O)n, CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—O-alkyl, CH—O-alkenyl, CH—O-alkynyl, CH—S-alkyl, CH—S-alkenyl, CH—S-alkynyl, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, or C-(halogen)2, wherein alkyl, alkenyl, or alkynyl may optionally be substituted; n is 0-2; such that when X is CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—O-alkyl, CH—O-alkenyl, CH—O-alkynyl, CH—S-alkyl, CH—S-alkenyl, CH—S-alkynyl, CH-halogen, or C-(halogen)2; then each R1 and R1′ is independently H, OH, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —C(O)O-(alkyl), —C(O)O(lower alkyl), —C(O)O-(alkenyl), —C(O)O-(alkynyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), —O(alkynyl), halogen, halogenated alkyl, —NO2, —NH2, —NH(lower alkyl), —N(lower alkyl)2, —NH(acyl), —N(acyl)2, —C(O)NH2, —C(O)NH(alkyl), —C(O)N(alkyl)2, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, or SCH-halogen; wherein alkyl, alkenyl, and/or alkynyl may optionally be substituted; and such that when X is O, S(O)n, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, or SCH-halogen; then each R1 and R1′ is independently H, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —C(O)O-(alkyl), —C(O)O(lower alkyl), —C(O)O-(alkenyl), —C(O)O-(alkynyl), halogenated alkyl, —C(O)NH2, —C(O)NH(alkyl), —C(O)N(alkyl)2, —C(H)═N—NH2, C(S)NH2, C(S)NH(alkyl), or C(S)N(alkyl)2, wherein alkyl, alkenyl, and/or alkynyl may optionally be substituted; each R2 and R3 independently is OH, NH2, SH, F, Cl, Br, I, CN, NO2, —C(O)NH2, —C(O)NH(alkyl), —C(O)N(alkyl)2, N3, optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, halogenated alkyl, —C(O)O-(alkyl), —C(O)O(lower alkyl), —C(O)O-(alkenyl), —C(O)O-(alkynyl), —O(acyl), —O(alkyl), —O(alkenyl), —O(alkynyl), —OC(O)NH2, NC, C(O)OH, SCN, OCN, —S(alkyl), —S(alkenyl), —S(alkynyl), —NH(alkyl), —NH(alkyl)2, —NH(alkenyl), —NH(alkynyl), an amino acid residue or derivative, a prodrug or leaving group that provides OH in vivo, or an optionally substituted 3-7 membered heterocyclic ring having O, S, and/or N independently as a heteroatom taken alone or in combination; each R2′ and R3′ independently is H; optionally substituted alkyl, alkenyl, or alkynyl; —C(O)O(alkyl), —C(O)O(lower alkyl), —C(O)O(alkenyl), —C(O)O(alkynyl), —C(O)NH2, —C(O)NH(alkyl), —C(O)N(alkyl)2, —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), halogen, halogenated alkyl, CF3, azido, cyano, NO2, —S(alkyl), —S(alkenyl), —S(alkynyl), NH2, —NH(alkyl), —N(alkyl)2, —NH(alkenyl), —NH(alkynyl), —NH(acyl), or —N(acyl)2; and Base is selected from the group consisting of:wherein
each R′ and R″ independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4 alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, or (C1-4 alkyl)0-2 aminomethyl; each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, N═NH, CONH2, CONH(alkyl), or CON(alkyl)2; each R4 is independently H, acyl, or C1-6 alkyl; and each Z is O, S, NH, N—OH, N—NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2. |
